News
Read the latest from M8.
Jul 24, 2024
M8 Pharmaceuticals, an Acino company, Signs Exclusive Agreement with LG Chem for Novel Treatments for Type 2 Diabetes and Osteoarthritis in Latin America
May 07, 2024
M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America
Apr 02, 2024
Acino announces new regional Leadership and hub to deliver on expanded presence and capabilities in LATAM following M8 acquisition Joel Barlan appointed as head of LATAM region
Mar 19, 2024
SERB Pharmaceuticals grants exclusive license to M8 Pharmaceuticals, an Acino company, to bring Voraxaze® (Glucarpidase) to cancer patients in Latin America
Dec 04, 2023
Acino Completes Acquisition of M8 Pharmaceuticals Significantly Expanding Presence and Capabilities In Latin America
Sep 20, 2023
Acino Significantly Expands Presence and Capabilities in Latin America Through Acquisition of M8 Pharmaceuticals
Aug 01, 2023
M8 Pharmaceuticals obtains market authorization for Barlo® (Carragelose®) nasal spray in Mexico
Feb 28, 2023
M8 Pharmaceuticals and Daewoong Pharmaceutical strengthen their strategic partnership by signing an exclusive licensing agreement for Envlo™ (Enavogliflozin) for Brazil and Mexico
Partner with Us
From go-to-market strategy and registration to access and long-term market presence, M8 is a purpose-built biopharmaceutical platform that supports the entire development-commercialization continuum.
Work with Us
Our motivated team fosters a supportive and positive culture fueled by the will to bring value to the patients of Latin America.
moksha8 Brazil announces a strategic alliance with HRA Pharma to commercialize Lysodren as the first step to build an Oncology line in this Market
Mar 26, 2018
moksha8 Brazil has entered into a Promotion and Distribution Agreement with HRA Pharma to commercialize Lysodren in Brazil as the first step to build an Oncology line in this country. Lysodren (mitotane tablets) is an oral chemotherapeutic agent indicated for the treatment of inoperable, functional or nonfunctional, adrenal cortical carcinoma and until now the only product available in the market for this type of cancer.
Adrenocortical carcinoma (ACC) is a rare and aggressive tumor which peaks in incidence during the first and fifth decades of life. ACC has an estimated worldwide annual incidence of 2 cases per million overall. The highest reported annual incidence of pediatric ACC in the world occurs in Southern Brazil (3.4 per million) and is 10-15-fold higher compared to the United States (U.S.), where the annual incidence of pediatric ACC is 0.2-0.3 cases per million*.
With this alliance and the new addition to its portfolio, moksha8 expects higher revenue growth and this expansion into the Oncology therapeutic area allows it to achieve a greater presence in the markets in which it operates.
The deal is also relevant for moksha8 because with it, the company continues its philosophy to bring innovative treatments to improving the health and quality of life to patients around the world, especially with rare and aggressive disease as adrenal cortical carcinoma.
HRA Pharm, a fast growing, innovative healthcare company with headquarters in Paris, France, affirmed that this partnership allows them to expand the international reach of its Endocrinology and Rare Disease Division in different markets such as Europe, United States, Canada, Brazil and South Korea and strengthens its position as a key player in Adrenal Cortical Carcinoma.
The companies expect strong results and a possible expansion of the relationship in the South America Country.
**Adrenocortical Carcinoma in Adults and Children: A Population-Based Outcomes Study involving 1,623 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1973-2012) Remedy Publications LLC Published 06 May, 2016